What Researchers Did
Researchers conducted a narrative review to explore the potential mechanisms, advantages, side effects, and uses of hyperbaric oxygen therapy (HBOT) as a supportive treatment for COVID-19 patients.
What They Found
The review suggests that hyperbaric oxygen therapy (HBOT) may boost tissue oxygenation by increasing plasma soluble oxygen levels and reduce inflammatory responses in COVID-19 patients. However, the authors noted that existing data on the efficacy of HBOT in COVID-19 patients is limited, indicating a lack of robust numerical evidence to support widespread use.
What This Means for Canadian Patients
For Canadian patients with COVID-19, hyperbaric oxygen therapy (HBOT) is a potential supportive treatment that could help with oxygenation and inflammation. However, given the limited existing data, its routine application is not yet recommended, and patients should consult their healthcare providers for personalized advice.
Canadian Relevance
This narrative review has no specific Canadian connection or data, as it is a general review of hyperbaric oxygen therapy for COVID-19 patients.
Study Limitations
A key limitation is the scarcity of robust clinical trial data on the efficacy of hyperbaric oxygen therapy specifically for COVID-19 patients.